Bioanalytical Method Validation & Troubleshooting Assistant
Validate bioanalytical methods and troubleshoot assay failures with FDA-aligned guidance
What You Can Do
You can design and execute bioanalytical method validations aligned with FDA Guidance for Industry and ICH guidelines, interpret complex validation data against regulatory acceptance criteria, and systematically troubleshoot analytical failures to identify root causes and corrective actions. This skill accelerates validation timelines by 20–30%, minimizes regulatory rework, and provides structured decision trees for problems that typically require expert consultation.
Features
Build fit-for-purpose protocols for accuracy, precision, selectivity, matrix effects, and stability studies tailored to your analyte's properties
Compare your results against FDA and ICH thresholds for intra/inter-assay CV, accuracy bias, and stability acceptance ranges
Diagnose root causes of method failures (sample prep, calibration, instrument drift, selectivity) and recommend targeted corrective actions
Determine whether your study requires full validation, partial validation, or cross-validation based on method changes and regulatory guidance
Ensure your validation documentation and data interpretation align with FDA and ICH Q2(R2) expectations
Evaluate ion suppression/enhancement, cross-talk, and interference patterns in LC-MS/MS and immunoassay workflows
Assess bench-top, autosampler, freeze-thaw, and long-term stability results against ICH stability acceptance criteria
Example Output
Example 1: Protocol Design for a New LC-MS/MS Biomarker Assay
✓ Validation scope: Full validation (new analyte, new method) ✓ Accuracy: 85–115% recovery across 3 QC levels ✓ Precision: ≤15% CV (intra-assay), ≤20% CV (inter-assay) ✓ Selectivity: <20% interference at retention time in 6 individual lots ✓ Matrix effects: Ion suppression <25% with post-column infusion ✓ Stability: 24h bench-top, 72h autosampler, 5 freeze-thaw cycles, 90 days long-term (−20°C) ✓ Sample size recommendations: 6 replicates per QC level, 3 analytical runs
Example 2: Troubleshooting Poor Precision (CV >20%)
Diagnosis pathway:
- Root cause: Inconsistent sample prep recovery → pH drift in extraction buffer
- Corrective action: Implement pH monitoring during QC preparation; tighten buffer tolerance to ±0.1 units
- Re-validation scope: Partial (sample prep modification) — repeat precision runs + stability confirmation
- Expected outcome: CV reduction to 12–15% range
Example 3: Matrix Effects Assessment Interpretation
✓ Ion suppression: −18% (acceptable, <25% threshold) ✓ Post-column recovery comparison: 94% vs. solution standard (acceptable, 85–115%) ✓ Selectivity in 6 lot blanks: 0 interference events ✓ Recommendation: Proceed to bioanalytical study; consider matrix-matched calibration for regulatory confidence
What's Included
- SKILL.md: Complete instruction file with workflows, decision trees, and structured prompts
- Validation Protocol Template: Editable protocol outline for accuracy, precision, selectivity, matrix effects, and stability study design
- Acceptance Criteria Reference Table: FDA and ICH guidance thresholds for CV, accuracy, bias, matrix effects, and analyte-specific recommendations
- Troubleshooting Decision Tree & Root Cause Framework: Systematic diagnostic flowchart for common analytical failures with corrective action recommendations
- Validation Data Interpretation Checklist: Point-by-point guide for evaluating results against regulatory expectations and identifying gaps before submission
Who It's For
- Bioanalytical Scientists — Developing, validating, and troubleshooting LC-MS/MS and immunoassay methods
- Analytical Chemists — Designing method protocols and managing validation studies for drug development programs
- QA/QC Specialists — Reviewing validation data, interpreting acceptance criteria, and documenting regulatory compliance
- Biomarker Assay Developers — Establishing validated assays for clinical diagnostics and biomarker research
- Regulatory Affairs Professionals — Supporting method validation sections in INDs, NDAs, and clinical study reports
Best For
- Method validation protocol design and approval — Building ICH/FDA-aligned validation studies before lab work begins
- Validation data interpretation and reporting — Evaluating results against acceptance criteria and documenting regulatory compliance
- Troubleshooting analytical failures — Systematically diagnosing root causes and recommending targeted corrective actions
- Cross-validation and partial validation decisions — Determining scope of re-validation needed for method modifications
- Regulatory documentation and submissions — Supporting IND, NDA, and bioanalytical study report sections with structured compliance checks
You might also like
Claude reviews your injection mold, stamping die, or precision tool designs for manufacturability, cost reduction opportunities, and tolerance optimization. You provide CAD specifications, material details, and production volume—Claude identifies specific design modifications, material alternatives, and tolerance adjustments that reduce tooling complexity and unit costs without compromising performance.
by kody-w
You systematically analyze workstations and work tasks for ergonomic hazards using industry-standard assessment methods (RULA, NIOSH, ISO 11228). You receive quantified risk scores, pinpointed hazard identification, and prioritized mitigation recommendations ranked by impact and feasibility. You can generate compliance-ready documentation and implement targeted interventions to reduce musculoskeletal injury risk.
by kody-w
Conduct comprehensive job risk assessments in minutes, generate detailed task analysis reports with biomechanical findings, and develop prioritized ergonomic interventions backed by OSHA and NIOSH guidelines. You'll identify risk factors, quantify hazard severity, and produce actionable recommendations that reduce worker injury rates and improve compliance documentation.
by kody-w
You can automate the validation of clinical trial data against protocol specifications, identify discrepancies including missing values, out-of-range results, protocol violations, and CRF inconsistencies. The skill generates audit-ready query documentation, categorizes anomalies by severity and type, resolves root causes systematically, and produces FDA inspection-ready reports that trace every data decision and corrective action for CDISC and regulatory submission.
by kody-w
Analyze your power system topology, coordinate protective devices for optimal selectivity and speed, and generate comprehensive arc flash hazard analyses compliant with IEEE 1584. You get fault current calculations, device coordination plots, and hazard risk assessments that guide equipment upgrades and safety training.
by kody-w
You can rapidly diagnose why your solid dose formulations are failing—whether due to poor flowability, insufficient hardness, moisture sensitivity, dissolution issues, or API degradation. The skill walks you through structured root-cause analysis, maps chemical interactions between your drug substance and excipients across pH, temperature, and moisture conditions, then prioritizes excipient replacements based on regulatory precedent and manufacturing feasibility. You'll document all decisions with clear rationale ready for CMC submissions.
by kody-w
This skill systematically analyzes your product designs to identify manufacturability issues early, saving costly revisions and manufacturing delays. It evaluates geometry, material selection, tolerances, assembly feasibility, and production process constraints. You get actionable feedback on cost drivers, process risks, and design optimizations before committing to production.
by kody-w
You consolidate parallel data streams from preclinical toxicology studies (clinical pathology, histopathology, body weight changes, organ weights, clinical observations, mortality) into coherent regulatory-compliant narratives. This skill synthesizes findings across 6–12 endpoints simultaneously, identifies NOAEL/LOAEL with biological justification, determines safety margins, interprets species-specific or sex-specific signals, and produces Results & Discussion sections that satisfy FDA/EMA reviewers while supporting appropriate dosing decisions for IND-enabling studies.
by kody-w